Astellas Pharma confirmed acquisition of MitoBridge. Astellas shelled out $225 million to acquire 100% of the equity in Mitobridge. The acquisition sets the tone for Astellas’s further research and development in diseases associated with mitochondrial dysfunctions and will enable the delivery of innovative new treatment options to patients. Astellas is still reviewing the impact of the completion of the acquisition on its financial results for the fiscal year ending March 31, 2018.